Groundbreaking Children’s Myopia Control Treatment Arrives in Canada

Millions of children across Canada are poised to benefit from a breakthrough therapy that addresses the fast-growing issue of myopia (nearsightedness), which is projected to negatively affect more than 50 per cent of the world’s population by 2050.
The CooperVision MiSight 1 day contact lens is now available for fitting by eyecare professionals (ECPs). It is the world’s first one-day soft contact lens clinically proven to substantially slow the progression of myopia in children.

Myopia significantly increases the risk of retinal detachment and myopic maculopathy, with even low myopia levels associated with a higher prevalence of glaucoma and cataracts. MiSight 1 day has been shown to reduce myopia progression by more than half, versus a single-vision one-day lens. Over three years, children wearing MiSight 1 day had 59 per cent less myopia progression and 52 per cent less axial elongation on average than those wearing a single-vision one-day lens.

The innovative contact lens is designed for children who have a myopia prescription from -0.25 to -6.00. Its ActivControl technology addresses both axial elongation and refractive error. Two treatment zones create myopic defocus, with image focus in front of the retina rather than behind it to slow axial elongation, while two correction zones fully correct myopia in all gaze positions. These zones ensure consistent myopic defocus across all gaze positions and prescriptions.

For ECPs, MiSight 1 day is as easy to fit as a single-vision soft contact lens. They benefit from repeatable outcomes with minimal chair time and follow-up visits, compared to therapies such as OrthoK. The lens was also designed for children’s ease of use and parental peace of mind.